Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen Inc

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

StockNews.com

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

Dogs of the Dow: 2 Stocks to Buy and 2 to Hold

The stock market has rebounded lately from the decline in the year's first half, thanks to better-than-expected corporate earnings and the expectation of easing inflationary pressure. However, a still uncomfortable inflation level and the possible aggressive rate hikes could keep the market volatile. The Dogs of the Dow investment strategy…

StockNews.com

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

StockNews.com

1 Biotech Stock That Stands out From the Rest

Amgen (AMGN) has undertaken several strategic growth initiatives to capitalize on the expanding biotech industry. In addition, several FDA drug approvals and other research and development breakthroughs make it well-positioned to witness significant growth in the near term, making it an ideal candidate for investors seeking to gain exposure in…

StockNews.com

5 "Strong Buy" Pharmaceutical Stocks to Own for the Long Haul

The inelastic demand and rising investments in research and development should drive the pharmaceutical industry’s growth in the long run. Therefore, pharmaceutical stocks AbbVie (ABBV), Amgen (AMGN), Catalyst (CPRX), Novo Nordisk (NVO), and Vertex (VRTX), which possess sound fundamentals, could be solid long-term investments. These stocks are rated Strong Buy…

StockNews.com

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

Can-Fite BioPharma Ltd (NYSE:CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses. At week 16, patients receiving…

Benzinga

2 Red-Hot Dow Jones Stocks With More Room to Run

Recessionary concerns and the Fed’s hawkish policy measures to combat high inflation are expected to extend the market correction. However, certain Dow Jones constituents with solid financials and bright growth prospects have been outperforming the benchmark index. So, Verizon (VZ) and Amgen (AMGN) could be solid investments now.

StockNews.com

Dogs of the Dow: 4 Stocks to Buy Now

Market sentiment was mostly unchanged on Monday, as investors await the May inflation report. Given the market uncertainties, we think investing in high-yielding dividend stocks that are part of the Dow Jones index—commonly known as the Dogs of the Dow—might the ideal strategy now. And our top choices among these…

StockNews.com

Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure

Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen

Molecular Partners AG's (NASDAQ:MOLN) collaborating partner Amgen Inc (NASDAQ:AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review. MP0310 is a dual-targeted compound targeting both FAP and 4-1BB that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming…

Benzinga

Amgen's Stelara-Based Biosimilar Shows Comparable Efficacy, Safety Profile For Psoriasis

Amgen Inc (NASDAQ:AMGN) announced preliminary results from a Phase 3 study of ABP 654 compared to Janssen Biotech Inc's Stelara (ustekinumab) in moderate to severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and Stelara. The primary analysis evaluated the percentage…

Benzinga

Analyzing Amgen Inc's Short Interest

Amgen Inc's (NASDAQ:AMGN) short percent of float has fallen 8.14% since its last report. The company recently reported that it has 24.47 million shares sold short, which is 4.4% of all regular shares that are available for trading.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Amgen's Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer

Amgen Inc (NASDAQ:AMGN) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7%,…

StockNews.com

4 Surging Dow Jones Stocks to Add to Your Watchlist

Despite volatile market conditions currently, owing in varying degrees to the Russia-Ukraine crisis and a hawkish Fed, a continuing economic rebound is still expected by many experts. With the slight easing of investor concerns, the Dow Jones Industrial Average has witnessed a solid recovery since mid-March. So, we think it…

Benzinga

Looking Into Amgen Inc's Recent Short Interest

Amgen Inc's (NASDAQ:AMGN) short percent of float has risen 123.83% since its last report. The company recently reported that it has 26.62 million shares sold short, which is 4.79% of all regular shares that are available for trading.

Benzinga

Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers. Devarakonda adds that the Verastem base case is supported by a…

Benzinga

Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer

Amgen Inc (NASDAQ: AMGN) announced the presentation of

Benzinga

Amgen's Q4 Sales Remain Flat As Its Biggest Product Flounders

Amgen Inc's (NASDAQ: AMGN) Q4 revenues incr

Benzinga

(AMGN) - Analyzing Amgen Inc's Short Interest

Amgen Inc's (NASDAQ:AMGN) short percent of float has risen 5.91% since last its last report. The company recently reported that it has 12.07 million shares sold short, which is 2.15% of all regular shares that are available for trading.

1 2 3 4

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.